From 1 April 2024 the National Health Insurance scheme reimbursed Epidyolex for Dravet syndrome from age two and tuberous sclerosis complex from age one. Patients must have failed at least three anti-epileptic drugs; Dravet patients must also have tried stiripentol, and tuberous sclerosis patients must have been assessed for surgery or vagus nerve stimulation. Only paediatric or neurology specialists may prescribe it, with annual prior review, and treatment stops if seizures fall by less than half after a year.[1]
Listed for context. No score change is recorded for Taiwan here.
References
- 澎湖縣政府衛生局 — 公告暫予支付含cannabidiol成分藥品（如Epidyolex）暨其藥品給付規定健保審字第1130051861號；發文日期113-03-04；附件2，自113年4月1日生效
Checked. The date and the event were compared with a source that was read.